Already a Bloomberg.com user?
Sign in with the same account.
Siga Technologies Inc. (SIGA) shouldn’t have to hand over 50 percent of the profits from a smallpox medicine to rival PharmAthene Inc. (PIP), lawyers for the drugmaker told an appeals court today.
To contact the reporter on this story: Phil Milford in Wilmington, Delaware at pmilford@bloomberg.net
To contact the editor responsible for this story: Andrew Dunn at adunn8@bloomberg.net